Part B · section 3

Consortium & partner confirmations

Four partners, four non-overlapping surfaces: the estimate, the record, the clinician, and the evidence.

Partners

AeroGlyphics

aeroglyphics.dev

Coordinator · estimation & evidence

Owns the VO₂ max estimation stack, the evidence dossier and WP6 regulatory work. 42 beta users across 3 clinical sites.

Medome

medome.ai

Patient spine · longitudinal record

Holds the complete health record, consent state and the longitudinal timeline every estimate is written back to.

SOAP Health

soap.health

Clinician surface · intake AI

Delivers the AI intake and documentation layer so a fitness trend reaches the clinician inside an existing workflow.

GoApercu SLAM

yc.goapercu.world

Model & regulatory evidence

SleepFM-based modelling, model cards and benchmarking against published survival endpoints.

Annex C — partner confirmation checklist

Planning envelope

AGREED

€3.85M consortium-agreed

C1 · AeroGlyphics

Retrospective imaging cohort

CONFIRMED

n=800 (600/200 split)

C2 · AeroGlyphics

Wearable cohort

CONFIRMED

n=500 participants

C3 · Medome

Prospective paired CPET

AGREED

n=240 participants

C4 · SOAP Health

SleepFM licence scope

PENDING

Research use; commercial + EEA extension due M6

C5 · GoApercu

Beta traction

CONFIRMED

42 users · 3 clinical sites

C6 · AeroGlyphics

Market reference

CONFIRMED

$42.4B (2024) → ~$141B (2030), Grand View

C7 · AeroGlyphics

ID	Item	Value	Owner	Status
C1	Planning envelope	€3.85M consortium-agreed	AeroGlyphics	AGREED
C2	Retrospective imaging cohort	n=800 (600/200 split)	AeroGlyphics	CONFIRMED
C3	Wearable cohort	n=500 participants	Medome	CONFIRMED
C4	Prospective paired CPET	n=240 participants	SOAP Health	AGREED
C5	SleepFM licence scope	Research use; commercial + EEA extension due M6	GoApercu	PENDING
C6	Beta traction	42 users · 3 clinical sites	AeroGlyphics	CONFIRMED
C7	Market reference	$42.4B (2024) → ~$141B (2030), Grand View	AeroGlyphics	CONFIRMED